Optiscan Imaging (OIL) Q3 2025 TU earnings summary

Executive summary

• Launched InForm™, a next-generation imaging device for pathology workflows, marking a major product milestone.

• Completed a comprehensive review of operations, resulting in key executive appointments and facility enhancements.

• Advanced product development pipeline, including veterinary and telepathology devices, and progressed clinical trial planning.

Financial highlights

• Received $1.775m R&D tax refund, $1.0m higher than previous years, supporting ongoing R&D activities.

• Net cash outflow from operating activities was ($0.125m), the lowest in two years, mainly due to the tax refund.

• Sales receipts for the quarter were $0.013m; year-to-date receipts reached $1.03m, surpassing FY24's $0.906m.

• Cash and cash equivalents at quarter end were $6.999m.

Outlook and guidance

• Anticipates further R&D, clinical, and regulatory milestones, with material progress in commercialisation expected in the coming year.

• Telepathology platform MVP and veterinary device prototype on track for Q4 FY25 delivery.

• Ongoing FDA engagement for InVueⓇ and InForm™ devices, with further feedback expected in Q4 FY25.